PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Phase 4

Completed

Conditions: Hemophilia A

Interventions: Biological: Moroctocog-alfa (AF-CC)

First Posted Date: 2020-05-20

Last Posted Date: 2021-05-03

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT04396639

Locations: 🇮🇳
Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India
🇮🇳
Christian Medical College and Hospital, Ludhiana, Punjab, India
🇮🇳
Nirmal Hospital, Surat, Gujarat, India

and more 2 locations

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy

Completed

Conditions: Breast Cancer

First Posted Date: 2020-05-19

Last Posted Date: 2023-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 242

Registration Number: NCT04394247

Locations: 🇺🇸
Syapse, San Francisco, California, United States

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06651600

First Posted Date: 2020-05-18

Last Posted Date: 2021-08-04

Lead Sponsor: Pfizer

Target Recruit Count: 164

Registration Number: NCT04390776

Locations: 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States

Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07054894

First Posted Date: 2020-05-14

Last Posted Date: 2022-07-12

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT04388878

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 20-valent pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine

First Posted Date: 2020-05-11

Last Posted Date: 2023-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 1997

Registration Number: NCT04382326

Locations: 🇺🇸
Palmetto Pediatrics, PA, North Charleston, South Carolina, United States
🇺🇸
Northwest Arkansas Pediatrics, Fayetteville, Arkansas, United States
🇺🇸
Houston Clinical Research Associates, Houston, Texas, United States

and more 95 locations

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13-valent pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine

First Posted Date: 2020-05-07

Last Posted Date: 2023-06-13

Lead Sponsor: Pfizer

Target Recruit Count: 1511

Registration Number: NCT04379713

Locations: 🇺🇸
Clinical Research Prime, Idaho Falls, Idaho, United States
🇺🇸
Idaho Falls Pediatrics, Idaho Falls, Idaho, United States
🇭🇺
Mimiped Bt, Gyor, Hungary

and more 90 locations

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Completed

Conditions: Renal Cell Carcinoma (RCC)

Interventions: Drug: Tyrosine kinase inhibitor (TKI)
Drug: Immuno-oncology (IO)

First Posted Date: 2020-05-05

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT04375150

Locations: 🇺🇸
Pfizer INC, New York, New York, United States

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

Phase 3

Active, not recruiting

Conditions: Hemophilia A

First Posted Date: 2020-04-30

Last Posted Date: 2024-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT04370054

Locations: 🇺🇸
UCSF IDS Pharmacy, San Francisco, California, United States
🇺🇸
University of California, San Francisco - Moffitt/Long Inpatient Hematology, San Francisco, California, United States
🇺🇸
University of California, San Francisco - Outpatient Hematology Clinic, San Francisco, California, United States

and more 33 locations

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Phase 3

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole Ointment
Drug: Crisaborole Placebo Vehicle

First Posted Date: 2020-04-24

Last Posted Date: 2022-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 391

Registration Number: NCT04360187

Locations: 🇯🇵
Iryouhoujinshadan Yamayurikai Tsujino. Kodomo Clinic, Kobe-City, Hyōgo, Japan
🇯🇵
Miyata Dermatology Clinic, Matsudo City, Chiba, Japan
🇯🇵
Chitose dermatology and plastic surgery clinic, Chitose Shi, Hokkaido, Japan

and more 36 locations

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4

Completed

Conditions: Carcinoma
Non-Small-Cell Lung

Interventions: Drug: Lorlatinib

First Posted Date: 2020-04-24

Last Posted Date: 2024-11-11

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT04362072

Locations: 🇮🇹
Policlinico "G. Rodolico", Catania, Italy
🇺🇸
UCI Medical Center/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University Cancer & Blood Center, Llc, Athens, Georgia, United States

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy